Literature DB >> 1850681

Renal and cardiovascular effects of exogenous insulin in healthy volunteers.

R O Gans1, L vd Toorn, H J Bilo, J J Nauta, R J Heine, A J Donker.   

Abstract

1. Renal and cardiovascular effects of three dosages of insulin [50 (Ins I), 300 (Ins II) and 500 (Ins III) m-units h-1 kg-1] were investigated in healthy males by using a euglycaemic clamp technique. On separate days, control experiments were carried out to correct for any circadian variation in the variables studied. 2. All three insulin dosages resulted in a marked decline in fractional sodium excretion (actual experiments: basal, 0.95 +/- 0.15%, Ins I, 0.79 +/- 0.10%, Ins II, 0.80 +/- 0.12%, Ins III, 0.84 +/- 0.08%; control experiments: basal, 0.96 +/- 0.10%, Ins I, 1.20 +/- 0.12%, Ins II, 1.53 +/- 0.15%, Ins III, 1.43 +/- 0.10%; means +/- SEM, P less than 0.005, analysis of variance). With the highest insulin dosage, the reduction in fractional sodium excretion tended to be less striking. This coincided with a rise in heart rate, pulse pressure and pulse rate-systolic blood pressure product (double product). Although blood pressure itself did not change, systolic blood pressure also tended to increase (actual experiments: basal, 133 +/- 5 mmHg, Ins I, 132 +/- 5 mmHg, Ins II, 139 +/- 5 mmHg, Ins III, 143 +/- 4 mmHg; control experiments: basal, 128 +/- 3 mmHg, Ins I, 129 +/- 3 mmHg, Ins II, 130 +/- 3 mmHg, Ins III, 133 +/- 3 mmHg; means +/- SEM, P = 0.09, analysis of variance). There was a positive correlation between the change in fractional sodium excretion and the change in systolic blood pressure over control values (r = 0.696, P less than 0.028).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850681     DOI: 10.1042/cs0800219

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

1.  Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects.

Authors:  P Stenvinkel; J Bolinder; A Alvestrand
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Insulin resistance and hypertension--implications for treatment.

Authors:  P A Rutherford; T H Thomas; R Wilkinson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

4.  Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss.

Authors:  Harvey J Sugerman; Luke G Wolfe; Domenic A Sica; John N Clore
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

5.  Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor.

Authors:  Swasti Tiwari; Nikhil Sharma; Pritmohinder S Gill; Peter Igarashi; C Ronald Kahn; James B Wade; Carolyn M A Ecelbarger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-18       Impact factor: 11.205

6.  Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II.

Authors:  R O Gans; H J Bilo; W W von Maarschalkerweerd; R J Heine; J J Nauta; A J Donker
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 7.  The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity.

Authors:  T Baba; S Neugebauer
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 8.  The inter-relationship between insulin resistance and hypertension.

Authors:  A Salvetti; G Brogi; V Di Legge; G P Bernini
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 9.  The pathogenesis of hypertension in obese subjects.

Authors:  P Weidmann; M de Courten; L Boehlen; S Shaw
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.